Published in Br J Pharmacol on August 28, 2014
Eph/ephrin sytem: In the quest of novel anti-angiogenic therapies. Br J Pharmacol (2014) 0.78
Design and evaluation of EphrinA1 mutants with cerebral protective effect. Sci Rep (2017) 0.75
Some quantitative uses of drug antagonists. Br J Pharmacol Chemother (1959) 41.90
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 7.14
New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci (2004) 4.22
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun (2005) 4.06
Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature (2010) 3.70
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol (2000) 3.09
Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol (2010) 3.07
EphA-Ephrin-A-mediated beta cell communication regulates insulin secretion from pancreatic islets. Cell (2007) 2.81
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med (2012) 2.65
EphB signaling directs peripheral nerve regeneration through Sox2-dependent Schwann cell sorting. Cell (2010) 2.54
The Concise Guide to PHARMACOLOGY 2013/14: catalytic receptors. Br J Pharmacol (2013) 2.29
Mechanisms of drug inhibition of signalling molecules. Nature (2006) 2.27
Eph receptors and ephrins restrict cell intermingling and communication. Nature (1999) 2.23
In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature (1999) 2.09
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res (2002) 1.96
Architecture of Eph receptor clusters. Proc Natl Acad Sci U S A (2010) 1.82
Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem (2008) 1.80
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res (2005) 1.57
MM-GB/SA rescoring of docking poses in structure-based lead optimization. J Chem Inf Model (2008) 1.53
The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell (2012) 1.50
The Eph family of receptors. Curr Opin Cell Biol (1997) 1.45
Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep (2009) 1.42
Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity. J Biol Chem (2006) 1.40
A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One (2012) 1.15
Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol (2008) 1.13
Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol (2011) 1.11
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis (2010) 1.08
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem (2009) 1.03
A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des (2011) 1.01
HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol (2013) 1.00
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation. PLoS One (2011) 1.00
Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood (2012) 0.99
Contact-dependent signaling during the late events of platelet activation. J Thromb Haemost (2003) 0.93
Therapeutic perspectives of Eph-ephrin system modulation. Drug Discov Today (2013) 0.89
Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor. ChemMedChem (2012) 0.86
Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol (2012) 0.85
Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase. Eur J Med Chem (2011) 0.84
Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites. J Agric Food Chem (2012) 0.83
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. Pharmacol Res (2011) 0.83
Inhibition of Eph receptor-ephrin ligand interaction by tea polyphenols. Pharmacol Res (2012) 0.80
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem (2013) 0.80
Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. ChemMedChem (2013) 0.76
Phosphotyrosine-containing proteins are concentrated in focal adhesions and intercellular junctions in normal cells. Proc Natl Acad Sci U S A (1985) 3.76
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A (2005) 2.96
SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism (1998) 2.65
EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron (2001) 2.53
The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene (2000) 2.46
Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene (2000) 2.45
Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science (1997) 2.40
Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther (2007) 2.38
A point mutation in the glutamate binding site blocks desensitization of AMPA receptors. Neuron (1998) 2.18
Percutaneous endoscopic gastrostomy: high mortality rates in hospitalized patients. Am J Gastroenterol (2000) 2.15
Talin is phosphorylated on tyrosine in chicken embryo fibroblasts transformed by Rous sarcoma virus. Proc Natl Acad Sci U S A (1986) 1.98
A patient education program is cost-effective for preventing failure of endoscopic procedures in a gastroenterology department. Am J Gastroenterol (2001) 1.81
Tyrosine phosphorylated proteins in different tissues during chick embryo development. J Cell Biol (1988) 1.76
Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol (1993) 1.70
Evaluation of the CTrach--an intubating LMA with integrated fibreoptic system. Br J Anaesth (2006) 1.57
An Eph receptor regulates integrin activity through R-Ras. Proc Natl Acad Sci U S A (1999) 1.57
Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr (2001) 1.56
Controlling vancomycin-resistant enterococci. Infect Control Hosp Epidemiol (1995) 1.55
Is the minimal model too minimal? Diabetologia (1996) 1.52
Etiology and risk factors of severe and protracted diarrhea. J Pediatr Gastroenterol Nutr (1995) 1.49
Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia (1999) 1.48
Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther (2009) 1.48
Trilayer graphene is a semimetal with a gate-tunable band overlap. Nat Nanotechnol (2009) 1.45
Comparison of Legionella pneumophila isolates by arbitrarily primed PCR and pulsed-field gel electrophoresis: analysis from seven epidemic investigations. J Clin Microbiol (1995) 1.40
Laparoscopic versus traditional fundoplication in the treatment of children with refractory gastro-oesophageal reflux. Ital J Gastroenterol Hepatol (1997) 1.39
Community outbreak of Legionnaires' disease: an investigation confirming the potential for cooling towers to transmit Legionella species. Clin Infect Dis (1996) 1.36
Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther (2009) 1.33
Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol (2005) 1.31
Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. EMBO J (1995) 1.28
Complex formation between EphB2 and Src requires phosphorylation of tyrosine 611 in the EphB2 juxtamembrane region. Oncogene (1998) 1.26
A novel signaling intermediate, SHEP1, directly couples Eph receptors to R-Ras and Rap1A. J Biol Chem (1999) 1.26
Shared and distinct functions of RAGS and ELF-1 in guiding retinal axons. EMBO J (1997) 1.25
Acute abdomen due to small bowel anisakiasis. Dig Liver Dis (2005) 1.25
Evaluation of Serratia peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicentre, double-blind, randomized trial versus placebo. J Int Med Res (1991) 1.22
Clinical score of 62 Italian patients with Cornelia de Lange syndrome and correlations with the presence and type of NIPBL mutation. Clin Genet (2007) 1.22
Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene (2000) 1.21
EphA4 constitutes a population-specific guidance cue for motor neurons. Dev Biol (2002) 1.19
EphA4/ephrin-A5 interactions in muscle precursor cell migration in the avian forelimb. Development (2001) 1.19
Five novel avian Eph-related tyrosine kinases are differentially expressed. Oncogene (1993) 1.17
Multiple in vivo tyrosine phosphorylation sites in EphB receptors. Biochemistry (1999) 1.17
IS6770, an enterococcal insertion-like sequence useful for determining the clonal relationship of clinical enterococcal isolates. J Infect Dis (1994) 1.17
In vivo tyrosine phosphorylation sites of activated ephrin-B1 and ephB2 from neural tissue. J Biol Chem (2001) 1.16
Aspergillus fumigatus-induced allergic airway inflammation alters surfactant homeostasis and lung function in BALB/c mice. Am J Respir Cell Mol Biol (2001) 1.15
Polarized expression of the receptor protein tyrosine kinase Cek5 in the developing avian visual system. Dev Biol (1995) 1.14
2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. J Med Chem (2008) 1.14
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol (2000) 1.14
Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. FEBS Lett (2002) 1.12
Tyrosine phosphorylation of L1 family adhesion molecules: implication of the Eph kinase Cek5. J Neurosci Res (1997) 1.09
Undermodeling affects minimal model indexes: insights from a two-compartment model. Am J Physiol (1999) 1.08
Expression and tyrosine phosphorylation of Eph receptors suggest multiple mechanisms in patterning of the visual system. Dev Biol (1998) 1.07
Pubertal adolescent male-female differences in insulin sensitivity and glucose effectiveness determined by the one compartment minimal model. Pediatr Res (2000) 1.07
Shot noise in ballistic graphene. Phys Rev Lett (2008) 1.07
Expression of EphA4, ephrin-A2 and ephrin-A5 during axon outgrowth to the hindlimb indicates potential roles in pathfinding. Dev Neurosci (2000) 1.06
cDNA cloning and characterization of a ligand for the Cek5 receptor protein-tyrosine kinase. J Biol Chem (1994) 1.05
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity. Life Sci (2005) 1.05
The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J Cell Biochem (2000) 1.03
Malate dehydrogenase of the cytosol. Ionizations of the enzyme-reduced-coenzyme complex and a comparison with lactate dehydrogenase. Biochem J (1978) 1.03
Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest (2000) 1.03
Identification of a new eph-related receptor tyrosine kinase gene from mouse and chicken that is developmentally regulated and encodes at least two forms of the receptor. New Biol (1991) 1.03
Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics (1994) 1.02
Multiple signaling interactions of Abl and Arg kinases with the EphB2 receptor. Oncogene (2001) 1.02
Immunolocalization of the receptor tyrosine kinase EphA4 in the adult rat central nervous system. Brain Res (1997) 1.01
The alpha v beta 3 integrin associates with a 190-kDa protein that is phosphorylated on tyrosine in response to platelet-derived growth factor. J Biol Chem (1993) 1.01
Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET. IEEE Trans Biomed Eng (1998) 1.01
Altered localization and cytoplasmic domain-binding properties of tyrosine-phosphorylated beta 1 integrin. J Cell Biol (1994) 1.01
Antimicrobial activity of some 1,2-benzisothiazoles having a benzenesulfonamide moiety. Arch Pharm (Weinheim) (1998) 1.00
An intercomparison between film dosimetry and diode matrix for IMRT quality assurance. Med Phys (2007) 1.00
Properties and applications of chemically functionalized graphene. J Phys Condens Matter (2013) 0.99
Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) (2008) 0.99
Frequency of the delta F508 mutation in a sample of 175 Italian cystic fibrosis patients. Hum Genet (1990) 0.99
Ephrin-A6, a new ligand for EphA receptors in the developing visual system. Dev Biol (2001) 0.99
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br J Pharmacol (2009) 0.98
The specificity of neurological signs in schizophrenia: a review. Schizophr Res (2000) 0.98
Proteoglycan depletion and magnetic resonance parameters of articular cartilage. Arch Biochem Biophys (2001) 0.97
alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care (1999) 0.96
Molecular and genomic characterisation of cryptic chromosomal alterations leading to paternal duplication of the 11p15.5 Beckwith-Wiedemann region. J Med Genet (2006) 0.96
Rac1 signaling regulates CTGF/CCN2 gene expression via TGFbeta/Smad signaling in chondrocytes. Osteoarthritis Cartilage (2008) 0.95
Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients. Ophthalmologica (2001) 0.94
Isolation and characterization of the fungal metabolite 3-O-methylviridicatin as an inhibitor of tumour necrosis factor alpha-induced human immunodeficiency virus replication. Antivir Chem Chemother (1998) 0.94
Reciprocal expression of the Eph receptor Cek5 and its ligand(s) in the early retina. Dev Biol (1997) 0.94
Different members of the fibroblast growth factor receptor family are specific to distinct cell types in the developing chicken embryo. Dev Biol (1993) 0.94
Eph receptors and ephrins in the developing chick cerebellum: relationship to sagittal patterning and granule cell migration. J Neurosci (2000) 0.93
Contact-dependent signaling during the late events of platelet activation. J Thromb Haemost (2003) 0.93
Use of the sulphite adduct of nicotinamide-adenine dinucleotide to study ionizations and the kinetics of lactate dehydrogenase and malate dehydrogenase. Biochem J (1978) 0.93
Lactase in man: a nonadaptable enzyme. Gastroenterology (1972) 0.93
Association of BoLA class II haplotypes with subclinical progression of bovine leukaemia virus infection in Holstein-Friesian cattle. Anim Genet (1996) 0.92
Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest (1997) 0.92
Motor responses of rat hypertrophic intestine following chronic obstruction. Neurogastroenterol Motil (2004) 0.92
A comparative study of 1-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P-450. Biochem Pharmacol (1988) 0.92
Synthesis and pharmacological evaluation of 2,5-cycloamino-5H-[1]benzopyrano[4,3-d]pyrimidines endowed with in vitro antiplatelet activity. Bioorg Med Chem Lett (2001) 0.91
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2010) 0.91
[Synthesis and pharmacologic activity of 9-R-octahydroindolo[2,3-a]quinolazine]. Farmaco Sci (1988) 0.90
Infection of Narcissus Roots by Aphelenchoides subtenuis. J Nematol (1993) 0.90
Seven-Tesla micro-MRI in early detection of acute arterial ischaemia: evolution of findings in an in vivo rat model. Radiol Med (2011) 0.90
Comparison of acetylcholine receptor-controlled cation flux in membrane vesicles from Torpedo californica and Electrophorus electricus: chemical kinetic measurements in the millisecond region. Proc Natl Acad Sci U S A (1982) 0.90
Malate dehydrogenase of the cytosol. Preparation and reduced nicotinamide-adenine dinucleotide-binding studies. Biochem J (1978) 0.89
Histidine residues and the enzyme activity of pig heart supernatant malate dehydrogenase. Biochem J (1974) 0.89